|Title||White to off-White Powder Enfuvirtide Acetate (T-20)|
|Description||White to off-White Powder Enfuvirtide Acetate (T-20) Sequence: CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2 Cas No.: 159519-65-0 Molecular Formula: C204H301N51O64 Molecular Weight: 4492 Purity (HPLC): 98.0%min. Appearance: White to off-white amorphous solid Single Impurity (HPLC): 0.5%max Amino Acid Composition: ±10% of theoretical Peptide Content (N%): ≥80.0% Water Content (Karl Fischer): ≤8.0% TrifluoroAcetate Content(HPIC): ≤12.0% MS (ESI): Consistent Mass Balance: 95.0~105.0% Description: Enfuvirtide powder is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected. Applications: Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).|
Please register or log in.